An open repository of community-contributed protocols sponsored by Nature Research.
Learn more about Protocol Exchange
Method Article
Sibaprasad Bhattacharyya
Imaging Probe Development Group
Corresponding Author
License:
This work is licensed under a CC BY-NC 3.0 License. Read Full License
A robust protocol has been developed for producing clinical-grade 89Zr-panitumumab as an immuno-PET probe to evaluate EGFR- targeted therapy. In this protocol, clinical-grade panitumumab is bio-conjugated with desferrioxamine chelate and subsequently radiolabeled with 89Zr resulting in high radiochemical yield (> 70 %, n = 3) and purity (> 98%, n = 3). All quality control (QC) tests were performed according to USP specifications (USP general chapter <823>). QC tests showed that the 89Zr-panitumumab met all specifications for human injection. This protocol describes a step-by-step method for the facile synthesis and quality control tests of 89Zr-panitumumab for medical use. The entire process of bioconjugation, radiolabeling, and all QC tests take about 5 h.
Keywords
89Zr, USP, Immuno-PET, EGFR
Figure 1
none
This is a list of supplementary files associated with this preprint. Click to download.
- supplement0.docx
Table 1 and Table 2 Tables
Loading...
Version History
CURRENT STATUS: Posted
Version 1
Posted 26 Sep, 2013
No community comments so far
Metrics
Comments: 0
HTML Views: ...
Associated Publications
Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas
by Sibaprasad Bhattacharyya, Karen Kurdziel, Ling Wei, +7
An open repository of community-contributed protocols sponsored by Nature Research.
Learn more about Protocol Exchange
Method Article
Sibaprasad Bhattacharyya
Imaging Probe Development Group
Corresponding Author
Version History
CURRENT STATUS: Posted
Version 1
Posted 26 Sep, 2013
No community comments so far
Metrics
Comments: 0
HTML Views: ...
License:
This work is licensed under a CC BY-NC 3.0 License. Read Full License
A robust protocol has been developed for producing clinical-grade 89Zr-panitumumab as an immuno-PET probe to evaluate EGFR- targeted therapy. In this protocol, clinical-grade panitumumab is bio-conjugated with desferrioxamine chelate and subsequently radiolabeled with 89Zr resulting in high radiochemical yield (> 70 %, n = 3) and purity (> 98%, n = 3). All quality control (QC) tests were performed according to USP specifications (USP general chapter <823>). QC tests showed that the 89Zr-panitumumab met all specifications for human injection. This protocol describes a step-by-step method for the facile synthesis and quality control tests of 89Zr-panitumumab for medical use. The entire process of bioconjugation, radiolabeling, and all QC tests take about 5 h.
Figure 1
none
This is a list of supplementary files associated with this preprint. Click to download.
- supplement0.docx
Table 1 and Table 2 Tables
Loading...
Associated Publications
Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas
by Sibaprasad Bhattacharyya, Karen Kurdziel, Ling Wei, +7